Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review
- 1 April 2014
- journal article
- review article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 2 (4) , 301-320
Abstract
No abstract availableKeywords
This publication has 197 references indexed in Scilit:
- A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive AdultsJournal of Clinical Immunology, 2013
- Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus ReactivationImmunity, 2012
- Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial InfectionsCell, 2012
- Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against TuberculosisCell Host & Microbe, 2011
- TuberculosisThe Lancet, 2011
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- The lta4h Locus Modulates Susceptibility to Mycobacterial Infection in Zebrafish and HumansCell, 2010
- In Vivo Requirement for Atg5 in Antigen Presentation by Dendritic CellsImmunity, 2010
- Autophagy, Immunity, and Microbial AdaptationsCell Host & Microbe, 2009
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialThe Lancet, 2008